Insmed catapults 30%, leading a biotech rally; but Mirum takes a bath
Insmed stock led a biotech rally Thursday, catapulting 30% on solid second-quarter sales for its new lung disease drug, Brinsupri.
Insmed stock led a biotech rally Thursday, catapulting 30% on solid second-quarter sales for its new lung disease drug, Brinsupri.